Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of somatic mutations in urine and plasma of Wilms tumor patients.

Cancer medicine - 1 Aug 2020

Miguez Ana Carolina Kerekes, Barros Bruna D de Figueiredo, de Souza Jorge E S, da Costa Cecília Maria L, Cunha Isabela Werneck, Barbosa Paula Nicole Vieira P, Apezzato Maria Lúcia P, de Souza Sandro J, Carraro Dirce Maria

Abstract excerpt

Tumor DNA has been detected in body fluids of cancer patients. Somatic tumor mutations are being used as biomarkers in body fluids to monitor chemotherapy response as a minimally invasive tool. In this study, we evaluated the potential of tracking somatic mutations in free DNA of plasma and urine collected from Wilms tumor (WT) patients for monitoring treatment response. Wilms tumor is a pediatric renal tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Infant

Share to Kidney Neoplasms

Share to Lung Neoplasms

Share to Neoadjuvant Therapy

Share to Wilms Tumor

Source

Open in PubMed Open full text

Identifiers

PMID: 32592321
DOI: 10.1002/cam4.3236
PMCID: PMC7433816

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of somatic mutations in urine and plasma of Wilms tumor patients.PMID 32592321Read ↗

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533Semantic proximity Read ↗

Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosisSemantic proximity Read ↗

Intra-tumor genetic heterogeneity in Wilms tumor samples.Semantic proximity Read ↗

Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in bloodSemantic proximity Read ↗

Discovery of Novel Potential Prognostic Marker and Targeted Therapy to Overcome Chemotherapy Resistance in an Advanced Stage Wilms’ TumorSemantic proximity Read ↗

Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.Semantic proximity Read ↗

Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications.Semantic proximity Read ↗

Genetic and chromosomal alterations in Kenyan Wilms Tumor.Semantic proximity Read ↗

Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms TumorsSemantic proximity Read ↗

Immune checkpoint markers and tumour mutation burden in Wilms tumour: a study of 59 cases.Semantic proximity Read ↗

Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

Genetic and Epigenetic Drivers of Wilms Tumor Predisposition in Russian Pediatric Patients: A Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.